Cerebrolysin: Regulatory Status
Current legal and regulatory status for Cerebrolysin across jurisdictions. This page reflects the most recent verified information and is updated as regulatory actions occur.
Back to Cerebrolysin overviewUnited States
Compoundable (503A)
Prescription required
Compounding status: not available through US compounding. WADA: not listed. approved in 44+ countries (NOT US, NOT EU centralized — though approved in several EU member states nationally). Used extensively in China, Russia, Eastern Europe, and parts of Asia/Latin America for stroke, TBI, and dementia. WHO Essential Medicines candidate. Cochrane reviews exist for several indications.
What This Means
Compoundable does not mean FDA approved.
Cerebrolysin is available through licensed 503A compounding pharmacies with a physician's prescription. This is a regulatory pathway, not an endorsement of efficacy for any specific indication. All use is off-label.
Reclassification is not the same as FDA approval.
Even if Cerebrolysin moves to Category 1, it remains an off-label therapeutic that requires physician supervision. Category 1 means it can be compounded under section 503A — it does not confer approved-drug status.